Needham Keeps Buy Rating on Autolus (AUTL) with a $10 Target

Autolus Therapeutics plc (NASDAQ:AUTL) is one of the 10 Best Penny Stocks to Buy for the Next 5 Years. On August 12, Needham reiterated a Buy rating on Autolus Therapeutics plc (NASDAQ:AUTL) with a $10 price target.

This decision came after Autolus Therapeutics plc (NASDAQ:AUTL) shared results for the second quarter of 2025.

The company had a strong second quarter, with $20.9 million in net product revenue from its product AUCATZYL, beating both Needham’s and market estimates. As a result, the firm raised its revenue estimates for Autolus Therapeutics plc (NASDAQ:AUTL) for 2025 and 2026.

Additionally, Autolus Therapeutics plc (NASDAQ:AUTL) is growing its Activated Treatment Centers (ATCs), increasing the number of centers to 46 as of August 12, 2025. The company aims to have over 50 centers by the end of the year.

Autolus Therapeutics plc (NASDAQ:AUTL) is an early commercial-stage biopharmaceutical company focused on developing and delivering next-generation T cell therapies for cancer and autoimmune diseases.

While we acknowledge the potential of AUTL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 11 Best Revenue Growth Stocks to Buy Now and 11 Best Under-the-Radar Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.